Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650572 · ClinicalTrials.gov registry record · Phase 1
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00650572 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 50 participants.
The verdict
NCT00650572, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase 1 study during which patients with advanced HER2+ solid malignancies or HER2+ metastatic breast cancer will receive investigational study drug ARRY-380. This study has 2 parts. In the first part, patients with advanced HER2+ solid malignancies, who have already received at least one previous standard therapy, will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 30 patients from the US will be enrolled in Part 1 (Completed). In the second part of this study, patients with HER2+ metastatic breast cancer, who have already received at least one previous standard therapy, will receive the best dose of study drug determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 20 patients from the US will be enrolled in Part 2 (Active, not recruiting).
Interventions
- DRUG ARRY-380, HER2 inhibitor; oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650572
The ClinicalTrials.gov registry entry for NCT00650572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARRY-380, HER2 inhibitor; oral is the first listed.
NCT00650572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650572 about?
NCT00650572 is a clinical study titled "A Study of ARRY-380 in Patients With Advanced HER2+ Cancer". This is a Phase 1 study during which patients with advanced HER2+ solid malignancies or HER2+ metastatic breast cancer will receive investigational study drug ARRY-380. This study has 2 parts. In the first part, patients with advanced HER2+ solid malignancies, who have already received at least one...
What is the current status of trial NCT00650572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2008-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00650572?
The interventions under investigation include: ARRY-380, HER2 inhibitor; oral (DRUG).
Who is sponsoring clinical trial NCT00650572?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.